- Home
- WHF vs PRQR Comparison
WHF vs PRQR Comparison
Compare WHF & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | PRQR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | Netherlands |
| Employees | 3 | 187 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.5M | 166.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | WHF | PRQR |
|---|---|---|
| Price | $7.51 | $1.60 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $7.75 | $7.25 |
| AVG Volume (30 Days) | 57.7K | ★ 768.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 13.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | $15.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.07 | $1.33 |
| 52 Week High | $9.66 | $3.10 |
Technical Indicators
Market Signals| Indicator | WHF | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 46.00 |
| Support Level | $6.80 | $1.36 |
| Resistance Level | $7.62 | $2.10 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 83.80 | 38.54 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.